Myriad Genetics Files $200M Universal Shelf Registration After Losing Well-Known Seasoned Issuer Status
MYGN sits 18% above its 52-week low of $3.76 on elevated volume (4.9× avg).
Summary
Myriad Genetics filed a $200 million universal shelf registration, replacing a prior filing due to the loss of its "well-known seasoned issuer" status, signaling potential significant dilution amidst recent financial losses.
Key Events · Financing and Capital Events · MYGN
-
Files $200 Million Universal Shelf Registration
The company has registered a variety of securities, including common stock, preferred stock, depositary shares, debt securities, and warrants, for potential future offerings up to an aggregate of $200 million. This is an authorization to sell, not an immediate issuance.
-
Loss of Well-Known Seasoned Issuer (WKSI) Status
This S-3 filing replaces a previous S-3ASR because Myriad Genetics no longer qualifies as a WKSI. This downgrade in status indicates a deterioration in the company's financial standing or market capitalization, making future capital raises potentially more complex and costly.
-
Significant Potential Dilution
The $200 million potential offering represents a substantial portion of the company's current market capitalization, indicating a high likelihood of significant future dilution for existing shareholders if the full amount is raised.
-
Concurrent with Negative Financial Results
This shelf registration is filed on the same day as the company's 10-K, which reported a $365.9 million net loss for 2025, including $319.4 million in goodwill and intangible asset impairments. This context suggests the capital raise is driven by financial necessity.
Analysis · MYGN · Life Sciences
Myriad Genetics has filed a universal shelf registration statement for up to $200 million in various securities, including common stock, preferred stock, debt, and warrants. This filing replaces a prior S-3ASR, as the company is no longer considered a "well-known seasoned issuer" (WKSI) following its recent 10-K filing. The loss of WKSI status is a significant downgrade, indicating a weakened financial position. The potential $200 million capital raise represents a substantial portion of the company's current market capitalization, signaling a high likelihood of future dilution. This comes on the same day as the company reported a significant net loss and impairments for 2025, highlighting an urgent need for capital and potentially challenging financing conditions.
At the time of this filing, MYGN was trading at $4.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $412.9M. The 52-week trading range was $3.76 to $14.73. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.